JPWO2019223733A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019223733A5 JPWO2019223733A5 JP2020565492A JP2020565492A JPWO2019223733A5 JP WO2019223733 A5 JPWO2019223733 A5 JP WO2019223733A5 JP 2020565492 A JP2020565492 A JP 2020565492A JP 2020565492 A JP2020565492 A JP 2020565492A JP WO2019223733 A5 JPWO2019223733 A5 JP WO2019223733A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- chain variable
- variable region
- antigen
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 12
- 102000036639 antigens Human genes 0.000 claims 12
- 108091007433 antigens Proteins 0.000 claims 12
- 239000012634 fragment Substances 0.000 claims 12
- 101000679851 Homo sapiens Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 102000050320 human TNFRSF4 Human genes 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 229930012538 Paclitaxel Natural products 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229960001592 paclitaxel Drugs 0.000 claims 3
- 238000006467 substitution reaction Methods 0.000 claims 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 claims 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 2
- 229960004942 lenalidomide Drugs 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000033581 fucosylation Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Claims (15)
（ｉｉ）（ａ）配列番号３のＨＣＤＲ１、（ｂ）配列番号１８のＨＣＤＲ２、（ｃ）配列番号５のＨＣＤＲ３を含む重鎖可変領域、及び（ｄ）配列番号６のＬＣＤＲ１、（ｅ）配列番号１９のＬＣＤＲ２、（ｆ）配列番号８のＬＣＤＲ３を含む軽鎖可変領域、
（ｉｉｉ）（ａ）配列番号３のＨＣＤＲ１、（ｂ）配列番号１３のＨＣＤＲ２、（ｃ）配列番号５のＨＣＤＲ３を含む重鎖可変領域、及び（ｄ）配列番号６のＬＣＤＲ１、（ｅ）配列番号７のＬＣＤＲ２、（ｆ）配列番号８のＬＣＤＲ３を含む軽鎖可変領域、又は
（ｉｖ）（ａ）配列番号３のＨＣＤＲ１、（ｂ）配列番号４のＨＣＤＲ２、（ｃ）配列番号５のＨＣＤＲ３を含む重鎖可変領域、及び（ｄ）配列番号６のＬＣＤＲ１、（ｅ）配列番号７のＬＣＤＲ２、（ｆ）配列番号８のＬＣＤＲ３を含む軽鎖可変領域を含み、
ヒトＯＸ４０に特異的に結合する抗体又はその抗原結合フラグメント。 (I) (a) HCDR (heavy chain complementarity determining regions) 1 of SEQ ID NO: 3, (b) HCDR2 of SEQ ID NO: 24, (c) heavy chain variable regions containing HCDR3 of SEQ ID NO: 5, and (d) sequence. LCDR (light chain complementarity determining regions) 1, (e) LCDR2 of SEQ ID NO: 19, and (f) light chain variable region comprising LCDR3 of SEQ ID NO: 8.
(Ii) (a) HCDR1 of SEQ ID NO: 3, (b) HCDR2 of SEQ ID NO: 18, (c) heavy chain variable region containing HCDR3 of SEQ ID NO: 5, and (d) LCDR1 of SEQ ID NO: 6, (e) sequence. LCDR2 of No. 19, (f) Light chain variable region containing LCDR3 of SEQ ID NO: 8,
(Iii) (a) HCDR1 of SEQ ID NO: 3, (b) HCDR2 of SEQ ID NO: 13, (c) heavy chain variable region containing HCDR3 of SEQ ID NO: 5, and (d) LCDR1 of SEQ ID NO: 6, (e) sequence. LCDR2 of No. 7, (f) a light chain variable region containing LCDR3 of SEQ ID NO: 8, (iv) (a) HCDR1 of SEQ ID NO: 3, (b) HCDR2 of SEQ ID NO: 4, (c) HCDR3 of SEQ ID NO: 5. Containing a heavy chain variable region comprising (d) LCDR1 of SEQ ID NO: 6, (e) LCDR2 of SEQ ID NO: 7, and (f) a light chain variable region comprising LCDR3 of SEQ ID NO: 8.
An antibody that specifically binds to human OX40 or an antigen-binding fragment thereof.
（ｉｉ）配列番号２０と少なくとも９０％、９１％、９２％、９３％、９４％、９５％、９６％、９７％、９８％若しくは９９％同一のアミノ酸配列を含む重鎖可変領域（ＶＨ）、及び配列番号２２と少なくとも９０％、９１％、９２％、９３％、９４％、９５％、９６％、９７％、９８％若しくは９９％同一のアミノ酸配列を含む軽鎖可変領域（ＶＬ）、
（ｉｉｉ）配列番号１４と少なくとも９０％、９１％、９２％、９３％、９４％、９５％、９６％、９７％、９８％若しくは９９％同一のアミノ酸配列を含む重鎖可変領域（ＶＨ）、及び配列番号１６と少なくとも９０％、９１％、９２％、９３％、９４％、９５％、９６％、９７％、９８％若しくは９９％同一のアミノ酸配列を含む軽鎖可変領域（ＶＬ）、又は
（ｉｖ）配列番号９と少なくとも９１％、９２％、９３％、９４％、９５％、９６％、９７％、９８％若しくは９９％同一のアミノ酸配列を含む重鎖可変領域（ＶＨ）、及び配列番号１１と少なくとも９１％、９２％、９３％、９４％、９５％、９６％、９７％、９８％若しくは９９％同一のアミノ酸配列を含む軽鎖可変領域（ＶＬ）を含む、
請求項１に記載の抗体又はその抗原結合フラグメント。 (I) Heavy chain variable region (VH) containing at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequence to SEQ ID NO: 26. , And a light chain variable region (VL) containing at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequence to SEQ ID NO: 28.
(Ii) Heavy chain variable region (VH) containing at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequence to SEQ ID NO: 20. , And a light chain variable region (VL) containing at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequence to SEQ ID NO: 22.
(Iii) A heavy chain variable region (VH) containing an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 14. , And a light chain variable region (VL) containing at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical amino acid sequence to SEQ ID NO: 16. Or (iv) a heavy chain variable region (VH) containing an amino acid sequence that is at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 9, and Includes a light chain variable region (VL) comprising an amino acid sequence that is at least 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 11.
The antibody according to claim 1 or an antigen-binding fragment thereof.
（ｉｉ）配列番号２０を含む重鎖可変領域（ＶＨ）、及び配列番号２２を含む軽鎖可変領域（ＶＬ）、
（ｉｉｉ）配列番号１４を含む重鎖可変領域（ＶＨ）、及び配列番号１６を含む軽鎖可変領域（ＶＬ）、又は
（ｉｖ）配列番号９を含む重鎖可変領域（ＶＨ）、及び配列番号１１を含む軽鎖可変領域（ＶＬ）を含む、
請求項１に記載の抗体又はその抗原結合フラグメント。 (I) Heavy chain variable region (VH) comprising SEQ ID NO: 26, and light chain variable region (VL) comprising SEQ ID NO: 28,
(Ii) Heavy chain variable region (VH) comprising SEQ ID NO: 20, and light chain variable region (VL) comprising SEQ ID NO: 22.
(Iii) Heavy chain variable region (VH) comprising SEQ ID NO: 14, light chain variable region (VL) comprising SEQ ID NO: 16, or (iv) heavy chain variable region (VH) comprising SEQ ID NO: 9, and SEQ ID NO: Containing a light chain variable region (VL) comprising 11.
The antibody according to claim 1 or an antigen-binding fragment thereof.
ヒトＯＸ４０のＨ１５３、Ｔ１５４、Ｉ１６５、Ｅ１６７及びＤ１７０からなる群から選択される１以上のアミノ酸残基を含むエピトープでヒトＯＸ４０に結合する、又は
ヒトＯＸ４０のＨ１５３、Ｉ１６５及びＥ１６７からなる群から選択される１以上のアミノ酸残基を含むエピトープでヒトＯＸ４０に結合する、又は
配列番号３０で、又は配列番号３０の内部でヒトＯＸ４０に結合する、
請求項１～６のいずれかに記載の抗体又はその抗原結合フラグメント。 An epitope containing one or more amino acid residues selected from the group consisting of H153 to D170 of human OX40 binds to or binds to human OX40.
An epitope containing one or more amino acid residues selected from the group consisting of H153, T154, I165, E167 and D170 of human OX40 binds to or binds to human OX40.
An epitope containing one or more amino acid residues selected from the group consisting of H153, I165 and E167 of human OX40 binds to or binds to human OX40.
Binds to human OX40 with SEQ ID NO: 30 or within SEQ ID NO: 30.
The antibody according to any one of claims 1 to 6 or an antigen-binding fragment thereof.
グリコシル化が減少し、若しくはグリコシル化されていないか、又はフコシル化が低い、請求項１～６のいずれかに記載の抗体又はその抗原結合フラグメント。 Have antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cellular cytotoxicity (CDC), or
The antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, wherein glycosylation is reduced, is not glycosylated, or fucosylation is low .
ＦｃドメインがＩｇＧ４のものである、請求項１～６のいずれかに記載の抗体又はその抗原結合フラグメント。 The Fc domain is of IgG1 or
The antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, wherein the Fc domain is that of IgG4 .
ＩｇＧ４がＳ２２８Ｐ置換及びＲ４０９Ｋ置換（ＥＵナンバリングシステムによる）を有する、請求項１０に記載の抗体又はその抗原結合フラグメント。 IgG4 has S228P substitution (according to EU numbering system) or
The antibody or antigen-binding fragment thereof according to claim 10 , wherein IgG4 has an S228P substitution and an R409K substitution (according to the EU numbering system) .
がんが、乳癌、頭頸部癌、胃癌、腎臓癌、肝臓癌、小細胞肺癌、非小細胞肺癌、卵巣癌、皮膚癌、中皮腫、リンパ腫、白血病、骨髄腫又は肉腫から任意に選択される、医薬組成物。 The pharmaceutical composition according to claim 12, which is used for treating or reducing the possibility of cancer.
The cancer is arbitrarily selected from breast cancer, head and neck cancer, gastric cancer, kidney cancer, liver cancer, small cell lung cancer, non-small cell lung cancer, ovarian cancer, skin cancer, mesothelioma, lymphoma, leukemia, myeloma or sarcoma. , Pharmaceutical composition .
任意に治療剤が、パクリタキセル又はパクリタキセル剤、ドセタキセル、カルボプラチン、トポテカン、シスプラチン、イリノテカン、ドキソルビシン、レナリドミド又は５－アザシチジンである、医薬組成物。 The pharmaceutical composition according to claim 13 , wherein the pharmaceutical composition is administered in combination with another therapeutic agent.
A pharmaceutical composition, wherein the therapeutic agent is optionally paclitaxel or a paclitaxel agent, docetaxel, carboplatin, topotecan, cisplatin, irinotecan, doxorubicin, lenalidomide or 5-azacitidine .
The pharmaceutical composition according to claim 14 , wherein the therapeutic agent is paclitaxel, lenalidomide or 5-azacitidine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024022697A JP2024056938A (en) | 2018-05-23 | 2024-02-19 | Anti-OX40 Antibodies and Methods of Use |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018088101 | 2018-05-23 | ||
| CNPCT/CN2018/088101 | 2018-05-23 | ||
| PCT/CN2019/088013 WO2019223733A1 (en) | 2018-05-23 | 2019-05-22 | Anti-ox40 antibodies and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024022697A Division JP2024056938A (en) | 2018-05-23 | 2024-02-19 | Anti-OX40 Antibodies and Methods of Use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021524256A JP2021524256A (en) | 2021-09-13 |
| JPWO2019223733A5 true JPWO2019223733A5 (en) | 2022-05-23 |
| JP7489922B2 JP7489922B2 (en) | 2024-05-24 |
Family
ID=68615676
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565492A Active JP7489922B2 (en) | 2018-05-23 | 2019-05-22 | Anti-OX40 Antibodies and Methods of Use |
| JP2024022697A Pending JP2024056938A (en) | 2018-05-23 | 2024-02-19 | Anti-OX40 Antibodies and Methods of Use |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024022697A Pending JP2024056938A (en) | 2018-05-23 | 2024-02-19 | Anti-OX40 Antibodies and Methods of Use |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210214452A1 (en) |
| EP (1) | EP3797123A4 (en) |
| JP (2) | JP7489922B2 (en) |
| KR (1) | KR20210013708A (en) |
| CN (1) | CN112566935A (en) |
| AU (1) | AU2019272384A1 (en) |
| BR (1) | BR112020023746A2 (en) |
| CA (1) | CA3100766A1 (en) |
| EA (1) | EA202092460A1 (en) |
| IL (1) | IL278772A (en) |
| MX (1) | MX2020012567A (en) |
| SG (1) | SG11202011024WA (en) |
| TW (1) | TW202016133A (en) |
| WO (1) | WO2019223733A1 (en) |
| ZA (1) | ZA202006931B (en) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3100766A1 (en) * | 2018-05-23 | 2019-11-28 | Beigene, Ltd. | Anti-ox40 antibodies and methods of use |
| EP4061844A4 (en) * | 2019-11-21 | 2023-12-06 | Beigene (Beijing) Co., Ltd. | Methods of cancer treatment with anti-ox40 antibody in combination with chemotherapeutic agents |
| MX2022006148A (en) * | 2019-11-21 | 2022-08-17 | Beigene Ltd | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies. |
| CN114728063B (en) * | 2019-11-21 | 2024-06-14 | 百济神州有限公司 | Treatment of cancer with anti-OX 40 antibodies and multiple kinase inhibitors |
| JP2023503230A (en) * | 2019-11-21 | 2023-01-27 | ベイジーン リミテッド | Methods of treating cancer using anti-OX40 antibodies in combination with PI3 kinase delta inhibitors |
| MX2022006147A (en) * | 2019-11-21 | 2022-06-17 | Beigene Ltd | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies. |
| EP4061845A4 (en) * | 2019-11-21 | 2023-12-13 | BeiGene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies |
| TW202144424A (en) * | 2020-04-17 | 2021-12-01 | 大陸商和記黃埔醫藥（上海）有限公司 | Anti-ox40 antibody and uses thereof |
| CN115260312A (en) * | 2021-04-30 | 2022-11-01 | 保诺科技（北京）有限公司 | Antibodies or antigen-binding fragments that bind to OX40 |
| WO2023109901A1 (en) | 2021-12-17 | 2023-06-22 | Shanghai Henlius Biotech, Inc. | Anti-ox40 antibodies and methods of use |
| WO2023109900A1 (en) | 2021-12-17 | 2023-06-22 | Shanghai Henlius Biotech, Inc. | Anti-ox40 antibodies, multispecific antibodies and methods of use |
| WO2023152116A1 (en) | 2022-02-08 | 2023-08-17 | Hookipa Biotech Gmbh | Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007334264A1 (en) * | 2006-11-15 | 2008-06-26 | Medarex, Inc. | Human monoclonal antibodies to BTLA and methods of use |
| PT2609118T (en) * | 2010-08-23 | 2017-03-22 | Univ Texas | Anti-ox40 antibodies and methods of using the same |
| BR112015023862A2 (en) | 2013-03-18 | 2017-10-24 | Biocerox Prod Bv | isolated antibody, isolated nucleic acid molecule, vector, host cell, method of enhancing an immune response, method of treating cancer, pharmaceutical composition, and isolated agonistic antibody |
| JP6526189B2 (en) * | 2014-07-03 | 2019-06-05 | ベイジーン リミテッド | Anti-PD-L1 antibodies and their use for therapy and diagnosis |
| TW201619200A (en) * | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | Humanized anti-OX40 antibodies and uses thereof |
| DE112016001013T5 (en) * | 2015-03-03 | 2017-12-21 | Kymab Limited | ANTIBODIES, USES AND METHODS |
| MX2017012278A (en) * | 2015-03-23 | 2018-05-23 | Bayer Pharma AG | Anti-ceacam6 antibodies and uses thereof. |
| PE20180926A1 (en) * | 2015-05-29 | 2018-06-08 | Bristol Myers Squibb Co | ANTIBODIES AGAINST MEMBER 4 OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY (OX40) AND ITS USES |
| CN114380908B (en) * | 2015-10-15 | 2023-03-17 | 苏州丁孚靶点生物技术有限公司 | anti-OX40 antibodies and uses thereof |
| GB201519481D0 (en) | 2015-11-04 | 2015-12-16 | Cancer Rec Tech Ltd | Immunomodulatory antibodies |
| JP2019526623A (en) * | 2016-08-08 | 2019-09-19 | ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | Anti-OX40 binding protein |
| CA3100766A1 (en) * | 2018-05-23 | 2019-11-28 | Beigene, Ltd. | Anti-ox40 antibodies and methods of use |
-
2019
- 2019-05-22 CA CA3100766A patent/CA3100766A1/en active Pending
- 2019-05-22 JP JP2020565492A patent/JP7489922B2/en active Active
- 2019-05-22 AU AU2019272384A patent/AU2019272384A1/en active Pending
- 2019-05-22 EA EA202092460A patent/EA202092460A1/en unknown
- 2019-05-22 CN CN201980034638.8A patent/CN112566935A/en active Pending
- 2019-05-22 SG SG11202011024WA patent/SG11202011024WA/en unknown
- 2019-05-22 KR KR1020207035920A patent/KR20210013708A/en active Search and Examination
- 2019-05-22 US US17/055,267 patent/US20210214452A1/en active Pending
- 2019-05-22 MX MX2020012567A patent/MX2020012567A/en unknown
- 2019-05-22 WO PCT/CN2019/088013 patent/WO2019223733A1/en unknown
- 2019-05-22 BR BR112020023746-9A patent/BR112020023746A2/en unknown
- 2019-05-22 EP EP19806419.8A patent/EP3797123A4/en active Pending
- 2019-05-23 TW TW108117808A patent/TW202016133A/en unknown
-
2020
- 2020-11-06 ZA ZA2020/06931A patent/ZA202006931B/en unknown
- 2020-11-17 IL IL278772A patent/IL278772A/en unknown
-
2024
- 2024-02-19 JP JP2024022697A patent/JP2024056938A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7257364B2 (en) | Anti-CD137 antibody | |
| US9180185B2 (en) | Combination therapy of anti-HER3 antibodies | |
| JP2019529373A5 (en) | Anti-Tim-3 antibody | |
| JP2018506964A5 (en) | ||
| JP2019536470A5 (en) | ||
| JP2018534933A5 (en) | ||
| CA3058960A1 (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| JP2020515577A5 (en) | ||
| US10975165B2 (en) | De-immunised anti-ERBB3 antibodies | |
| RU2019139093A (en) | PHARMACEUTICAL COMPOSITION BASED ON ANTIBODY TO PD-L1 AND ITS APPLICATION | |
| AU2020283817A1 (en) | TIGIT and PD-1/TIGIT-binding molecules | |
| RU2020127196A (en) | ANTIBODY AGAINST 4-1BB, ITS ANTIGEN-BINDING FRAGMENT AND ITS MEDICAL APPLICATIONS | |
| JPWO2019223733A5 (en) | ||
| JP2020522280A5 (en) | ||
| JP2020522281A5 (en) | ||
| JP2018533569A5 (en) | ||
| JPWO2019224711A5 (en) | ||
| JPWO2020043152A5 (en) | ||
| US20240101674A1 (en) | Pd1 and vegfr2 dual-binding agents | |
| JP2021512652A5 (en) | ||
| TW202108631A (en) | A anti-cd47 antigen binding protein and use thereof | |
| US20220389088A1 (en) | Anti-angiopoietin-like 4 (angptl4) antibodies and methods of use | |
| JPWO2020218951A5 (en) | ||
| RU2022101756A (en) | ANTIBODIES TO TIGIT AND THEIR USE | |
| RU2021118025A (en) | An isolated bispecific antibody that specifically binds to CD47 and PD-L1 |